bioRxiv preprint doi: https://doi.org/10.1101/2021.03.18.435984; this version posted March 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Toulmin, S.A. et al. 1 Type II alveolar cells with constitutive expression of MHCII and limited antigen presentation capacity contribute to improved respiratory viral disease outcomes Sushila A. Toulmin1,2*, Chaitali Bhadiadra1, Andrew J. Paris3, Jeffrey H. Lin2, Jeremy Katzen3, Maria C. Basil4, Edward E. Morrisey4, 5, 6, 7, G. Scott Worthen8,9, and Laurence C. Eisenlohr1,10*. 1Division of Protective Immunity, Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4Department of Medicine, Penn-CHOP Lung Biology Institute, University of Pennsylvania, Philadelphia, PA, USA. 5Penn Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6Penn Institute for Regenerative Medicine, Perelman School of Medicine, Philadelphia, PA, USA. 7Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 8Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 9Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 10Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. *Correspondence should be addressed to S.A.T. (
[email protected]) and L.C.E.